Neurology News

Aimovig appeared safe and effective for treating migraine with and without history of aura, according to results of a secondary analysis of randomized clinical trials published in JAMA Neurology.

Age at pediatric stroke has a significant impact on post-stroke recovery and affects long-term cognitive outcome regardless of lesion size and lesion location, according to results of a cross-sectional study published in Neurology.

Researchers observed differences in survival between antiseizure medications in post-stroke epilepsy, with lamotrigine and levetiracetam appearing to be reasonable first-line treatment options, according to a study in JAMA Neurology.

Pharma Two B, a company that uses reformulations and combinations of previously approved drugs to develop new therapies for neurological indications, announced its novel therapy for Parkinson’s disease met primary and secondary endpoints.

Anticoagulation with rivaroxaban for patients with atrial fibrillation aged 65 years or more was associated with greater risk for major ischemic and hemorrhagic events compared with apixaban, according to data published in JAMA.

The FDA granted orphan drug designation to silmitasertib for treatment of medulloblastoma.

Neuroscience firm Inscopix, Inc. introduced a cloud-based data management system intended to ease collection, organization and sharing of neuroscience research.

Biogen Inc. and Eisai Co. Ltd. announced plans to submit their phase 4 protocol for Aduhelm to the FDA in March 2022.

Surgeons at Lenox Hill Hospital are recruiting patients for a first-in-human, single arm, open-label phase 1 clinical trial investigating the safety and feasibility of using belly fat to treat recurrent glioblastoma.

The American Heart Association announced a $10 million initiative to fund studies of long-term effects of COVID-19 on heart and brain health.